Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Net loss	$ (27,747)	$ (16,101)
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development assets		8,000
Share-based compensation expense	6,202	538
Depreciation expense	6	5
Amortization of operating right-of-use assets	47	44
Non-cash interest expense		7
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	422	(2,542)
Deposits and other long-term assets	4	(26)
Accounts payable	(1,043)	484
Accrued expenses and other current liabilities	595	(101)
Operating lease liabilities	(49)	(51)
Net cash used in operating activities	(21,563)	(9,743)
Cash flows from investing activities
Cash paid for acquired in-process research and development assets		(8,000)
Property and equipment expenditures	(15)
Cash used in investing activities	(15)	(8,000)
Cash flows from financing activities
Proceeds from issuance of Series B redeemable convertible preferred shares, net of issuance costs		129,757
Payments of financing issuance costs		(872)
Net cash provided by financing activities		128,885
Net increase (decrease) in cash and cash equivalents	(21,578)	111,142
Cash and cash equivalents, beginning of period	284,309	43,728
Cash and cash equivalents, end of period	262,731	154,870
Supplemental disclosures of noncash activities
Deferred offering costs not yet paid		$ 686